Carcinoma, Hepatocellular

Inclusion Criteria

- Male or Female age >/= 18 years of age
 - Life expectancy >/= 12 weeks
 - Histologically or cytologically confirmed diagnosis of HCC, unresectable advanced or metastatic
 - Liver function status of Child-Pugh class A. Child-Pugh status based on clinical findings and laboratory results during the screening period
 - Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
 - Patients must have at least one naïve (not previously treated by locoregional therapy) uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1
 - Adequate bone marrow, liver and renal function

Exclusion Criteria

- Previous or concurrent cancer other than HCC, except for cervical carcinoma in situ, basal cell carcinoma, superficial bladder tumors.
 - History of cardiac disease: Congestive heart failure (CHF), unstable angina, arrhythmias, Uncontrolled hypertension
 - Clinically significant GI bleeding (CTCAE grade 3 or higher) within 30 days 
 - Renal failure requiring hemo- or peritoneal dialysis
 - Known human immunodeficiency virus (HIV) infection
 - Known history or symptomatic metastatic brain or meningeal tumors
 - History of organ allograft.
 - History of interstitial lung disease (ILD).
 - Excluded previous therapies and medications:
 -- Prior use of systemic anti-cancer treatment for HCC including cytotoxic chemotherapy, targeted agents, or any experimental therapy
 -- Radiotherapy within 4 weeks prior to start of study treatment
 -- Any other investigational agents within 4 weeks from the first dose of study treatment
 -- Major surgery within 4 weeks of start of study 
 -- Concomitant use of strong inhibitors and strong inducers of CYP3A4